H.R. 5094 repeals two specific provisions of the reconciliation law identified as sections 71120 and 71203 of Public Law 119–21. Section 2 of the bill revokes the statutory changes to Medicaid cost‑sharing rules created by section 71120 and rescinds the amounts appropriated under 71120(c).
Section 3 withdraws the change that removed the exclusion for orphan drugs from the Medicare Drug Price Negotiation Program by repealing section 71203.
The practical effect is procedural: the bill directs that title XIX (Medicaid) and title XI (administrative provisions relevant to the drug negotiation program) be applied as if those two reconciliation sections had never been enacted. That restores the pre‑reconciliation legal baseline for Medicaid cost sharing and preserves the orphan‑drug carve‑out from federal negotiation authority—moves with immediate budgetary and market consequences for Medicare, Medicaid, manufacturers, and patients dependent on high‑cost orphan therapies.
At a Glance
What It Does
The bill repeals section 71120 (Medicaid cost‑sharing changes) and section 71203 (removal of the orphan‑drug exclusion) from Public Law 119–21, and rescinds the amounts appropriated under 71120(c). It instructs federal law to be applied as though those two sections had never been enacted.
Who It Affects
Directly affects Medicaid enrollees and state Medicaid programs (title XIX), the Medicare Drug Price Negotiation Program and Medicare Part D stakeholders (title XI), and pharmaceutical manufacturers of orphan drugs. It also touches CMS and Treasury for implementation and budget accounting.
Why It Matters
The bill reverses two recent reconciliation changes that change cost exposure for low‑income patients and remove a statutory protection for orphan drugs. That combination has implications for patient out‑of‑pocket costs, federal and state budgets, drug negotiation leverage, and incentives for rare disease drug development.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H.R. 5094 is short and surgical: it targets two discrete statutory edits made by Public Law 119–21 and deletes them. For Medicaid, the bill nullifies whatever alterations section 71120 made to cost‑sharing rules and simultaneously cancels any funding that section 71120(c) had provided.
For the Medicare drug negotiation program, it restores the prior law that excluded orphan drugs from negotiation by striking section 71203. The bill does not replace those provisions with new policy; it simply reverts the statutory baseline.
Practically, the “as if never enacted” language means agencies must treat Titles XIX and XI the way they were written before the reconciliation changes. That can require undoing regulatory or programmatic steps—revoking guidance, reversing operational changes, and telling states or plan sponsors to continue to follow the earlier statutory framework.
The bill does not specify timelines or transitional rules, so the agencies (principally CMS) will face follow-up choices about sequencing and communication.On budgets and markets, two countervailing effects are visible from the text. Rescinding the amounts in 71120(c) reduces whatever new spending or transfers Congress previously authorized for that change, but restoring the orphan‑drug exclusion preserves a statutory barrier to negotiating prices for therapies often priced well above other drugs.
That preserves revenue streams for manufacturers of orphan products and maintains the negotiation program’s narrower scope. The text does not create alternative offsets or new funding streams.Because the bill simply directs a legal reversion, implementation will be administrative and potentially messy.
CMS and other agencies will have to determine which program actions were final, which state plan amendments depend on the repealed sections, and whether any benefits or cost‑sharing changes already implemented must be rolled back or left in place. The bill leaves those operational details to executive branch agencies and to subsequent appropriations and guidance.
The Five Things You Need to Know
The bill repeals section 71120 of Public Law 119–21, which the reconciliation law used to change Medicaid cost‑sharing requirements.
It rescinds the amounts that were appropriated under section 71120(c) rather than transferring or reprogramming them.
The bill repeals section 71203 of Public Law 119–21, restoring the statutory exclusion that keeps orphan drugs out of the Medicare Drug Price Negotiation Program.
Both repeals are carried out by instructing Titles XIX and XI to be applied “as if” the repealed sections had never been enacted—effectively reverting to the pre‑reconciliation statutory baseline.
The bill does not add new regulatory language or replacement programs; it relies on agencies (primarily CMS) to implement the reversion and on appropriations processes to resolve any budgetary consequences.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — 'Protect Patients from Costly Care Act'
This is the naming clause; it does not create operative obligations. The presence of an explicit short title signals the bill’s intent to be read as a targeted repeal rather than a broader policy reform package. Practically, it has no substantive effect on implementation.
Repeal of Medicaid cost‑sharing changes (repeal of sec. 71120)
This clause strikes section 71120 from Public Law 119–21 and orders that title XIX of the Social Security Act be applied as though that section and its amendments never existed. It also rescinds the amounts appropriated under subsection (c) of the repealed provision. The operative consequence is twofold: statutory reversion of Medicaid cost‑sharing law to the prior text, and the removal of any new federal funds that had been tied to implementing the now‑repealed change. Administratively, states and CMS will need to identify which state plan actions, eligibility templates, or guidance derived from 71120 and unwind or adapt them.
Repeal of change to orphan‑drug exclusion (repeal of sec. 71203)
This provision strikes section 71203 from the reconciliation law and requires title XI to be read as if that amendment had not occurred, thereby restoring the pre‑existing statutory exclusion that prevents orphan drugs from being included in the Medicare Drug Price Negotiation Program. The immediate legal effect is to remove the statutory authority to negotiate prices for orphan‑designated therapies under the mechanism created by Public Law 119–21; practically, agency negotiators and program administrators must adjust their negotiation lists and related procedures accordingly.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicaid enrollees who would have faced higher or different cost‑sharing under the repealed changes — by restoring the previous legal baseline, the bill protects existing out‑of‑pocket rules for low‑income beneficiaries.
- Manufacturers of orphan drugs — reinstating the orphan‑drug exclusion preserves their protection from federal price negotiations and safeguards existing revenue structures for rare‑disease therapies.
- Rare disease patient advocacy groups that opposed inclusion of orphan drugs in negotiation — they retain a statutory firewall that supporters argue protects incentives for R&D.
- Stakeholders that prefer regulatory continuity (some states and plan sponsors) — they avoid operational shifts tied to newly enacted cost‑sharing or negotiation rules.
Who Bears the Cost
- Medicare beneficiaries and payers who would have benefited from lower negotiated prices for orphan drugs — removing orphan drugs from negotiation foregoes potential price reductions.
- Federal negotiators and budget managers seeking savings from broader negotiation authority — the bill narrows the negotiation tool and reduces potential bargaining leverage.
- CMS and other federal agencies charged with implementation — they must unwind actions, adjust guidance, and resolve transitional questions without statutory detail on sequencing.
- States that anticipated or relied on the funds appropriated under 71120(c) for implementing the cost‑sharing changes — those appropriations are rescinded, creating potential funding gaps or necessitating state‑level adjustments.
Key Issues
The Core Tension
The central dilemma is a classic access versus cost‑control trade‑off: protect vulnerable patients from higher or uncertain Medicaid cost‑sharing and preserve statutory incentives for orphan‑drug development, or broaden negotiation and cost‑sharing reforms to reduce federal drug spending and lower prices for high‑cost therapies—each choice helps one constituency while imposing costs on another, and H.R. 5094 decisively favors reversion to the pre‑reconciliation baseline without offering compensating measures.
The bill’s brevity creates implementation ambiguity. Telling Titles XIX and XI to be applied “as if” specified sections had not been enacted leaves open whether actions already taken under the repealed provisions must be reversed, or whether they can stand if administratively final.
For example, if a state implemented a cost‑sharing change and adjusted provider or beneficiary billing practices, agencies will need to decide whether to require retroactive corrections, prospective changes, or to grandfather existing arrangements. The statute is silent on transitional rules, effective dates, and how to handle contractual or payment obligations entered into under the now‑repealed authorities.
There is also a budgetary and incentive trade‑off baked into the text. Rescinding 71120(c) removes a previously authorized appropriation, which reduces or cancels an expected federal outlay; at the same time, restoring the orphan‑drug exclusion blocks a potential source of prescription drug savings from the negotiation program.
That combination may produce offsets in opposite directions—lost savings from narrower negotiations versus immediate reductions in authorized spending—complicating scorekeeping, appropriations, and longer‑term fiscal planning. Finally, because the bill does not propose alternative policy to either limit patient exposure or to replace negotiation authority, it leaves unresolved whether Congress intends a different approach to manage drug prices or revise Medicaid cost‑sharing through separate legislation.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.